Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland

(1) Background: To report and analyze the presence of residual symptoms after SARS-CoV-2 infection among Polish patients with multiple sclerosis (MS) treated with different disease-modifying therapies (DMTs). (2) Methods: The study included 426 individuals with MS treated with DMTs and confirmed SAR...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Agata Czarnowska, Katarzyna Kapica-Topczewska, Olga Zajkowska, Monika Adamczyk-Sowa, Katarzyna Kubicka-Bączyk, Natalia Niedziela, Paweł Warmus, Alicja Kalinowska-Łyszczarz, Karolina Kania, Agnieszka Słowik, Marcin Wnuk, Monika Marona, Klaudia Nowak, Halina Bartosik-Psujek, Beata Lech, Adam Perenc, Małgorzata Popiel, Marta Kucharska-Lipowska, Monika Chorąży, Joanna Tarasiuk, Anna Mirończuk, Jan Kochanowicz, Anetta Lasek-Bal, Przemysław Puz, Katarzyna Maciejowska, Sławomir Wawrzyniak, Anna Niezgodzińska-Maciejek, Anna Pokryszko-Dragan, Ewa Gruszka, Sławomir Budrewicz, Marta Białek, Jacek Zwiernik, Anna Michałowska, Krzysztof Nosek, Beata Zwiernik, Bożena Lewańczyk, Waldemar Brola, Alina Kułakowska
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	multiple sclerosis COVID-19 SARS-CoV-2 disease modifying therapies residual symptoms Medicine R
Acceso en línea:	https://doaj.org/article/812471485cba43638a8b703fa750442d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:812471485cba43638a8b703fa750442d
record_format	dspace
spelling	oai:doaj.org-article:812471485cba43638a8b703fa750442d2021-11-25T18:00:38ZSymptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland10.3390/jcm102252252077-0383https://doaj.org/article/812471485cba43638a8b703fa750442d2021-11-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/22/5225https://doaj.org/toc/2077-0383(1) Background: To report and analyze the presence of residual symptoms after SARS-CoV-2 infection among Polish patients with multiple sclerosis (MS) treated with different disease-modifying therapies (DMTs). (2) Methods: The study included 426 individuals with MS treated with DMTs and confirmed SARS-CoV-2 infection from 12 Polish MS centers. The data were collected through to 31 May 2021. The information included demographics, specific MS characteristics, course of SARS-CoV-2 infection, and residual (general and neurological) symptoms lasting more than four and 12 weeks after the initial infection. The results were obtained using maximum likelihood estimates for odds ratio and logistic regression. (3) Results: A total of 44.84% patients with MS reported symptoms lasting between four and 12 weeks after the initial infection; 24.41% people had symptoms that resolved up to 12 weeks, and 20.42% patients had symptoms that lasted over 12 weeks. The most common symptoms were: fatigue, disturbance of concentration, attention, and memory, cognitive complaints, and headache. None of the DMTs were predisposed to the development of residual symptoms after the initial infection. A total of 11.97% of patients had relapse three months prior or after SARS-CoV-2 infection. (4) Conclusion: Almost half of individuals with MS treated with different DMTs had residual symptoms after SARS-CoV-2 infection. None of the DMTs raised the probability of developing post-acute COVID symptoms.Agata CzarnowskaKatarzyna Kapica-TopczewskaOlga ZajkowskaMonika Adamczyk-SowaKatarzyna Kubicka-BączykNatalia NiedzielaPaweł WarmusAlicja Kalinowska-ŁyszczarzKarolina KaniaAgnieszka SłowikMarcin WnukMonika MaronaKlaudia NowakHalina Bartosik-PsujekBeata LechAdam PerencMałgorzata PopielMarta Kucharska-LipowskaMonika ChorążyJoanna TarasiukAnna MirończukJan KochanowiczAnetta Lasek-BalPrzemysław PuzKatarzyna MaciejowskaSławomir WawrzyniakAnna Niezgodzińska-MaciejekAnna Pokryszko-DraganEwa GruszkaSławomir BudrewiczMarta BiałekJacek ZwiernikAnna MichałowskaKrzysztof NosekBeata ZwiernikBożena LewańczykWaldemar BrolaAlina KułakowskaMDPI AGarticlemultiple sclerosisCOVID-19SARS-CoV-2disease modifying therapiesresidual symptomsMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5225, p 5225 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	multiple sclerosis COVID-19 SARS-CoV-2 disease modifying therapies residual symptoms Medicine R
spellingShingle	multiple sclerosis COVID-19 SARS-CoV-2 disease modifying therapies residual symptoms Medicine R Agata Czarnowska Katarzyna Kapica-Topczewska Olga Zajkowska Monika Adamczyk-Sowa Katarzyna Kubicka-Bączyk Natalia Niedziela Paweł Warmus Alicja Kalinowska-Łyszczarz Karolina Kania Agnieszka Słowik Marcin Wnuk Monika Marona Klaudia Nowak Halina Bartosik-Psujek Beata Lech Adam Perenc Małgorzata Popiel Marta Kucharska-Lipowska Monika Chorąży Joanna Tarasiuk Anna Mirończuk Jan Kochanowicz Anetta Lasek-Bal Przemysław Puz Katarzyna Maciejowska Sławomir Wawrzyniak Anna Niezgodzińska-Maciejek Anna Pokryszko-Dragan Ewa Gruszka Sławomir Budrewicz Marta Białek Jacek Zwiernik Anna Michałowska Krzysztof Nosek Beata Zwiernik Bożena Lewańczyk Waldemar Brola Alina Kułakowska Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland
description	(1) Background: To report and analyze the presence of residual symptoms after SARS-CoV-2 infection among Polish patients with multiple sclerosis (MS) treated with different disease-modifying therapies (DMTs). (2) Methods: The study included 426 individuals with MS treated with DMTs and confirmed SARS-CoV-2 infection from 12 Polish MS centers. The data were collected through to 31 May 2021. The information included demographics, specific MS characteristics, course of SARS-CoV-2 infection, and residual (general and neurological) symptoms lasting more than four and 12 weeks after the initial infection. The results were obtained using maximum likelihood estimates for odds ratio and logistic regression. (3) Results: A total of 44.84% patients with MS reported symptoms lasting between four and 12 weeks after the initial infection; 24.41% people had symptoms that resolved up to 12 weeks, and 20.42% patients had symptoms that lasted over 12 weeks. The most common symptoms were: fatigue, disturbance of concentration, attention, and memory, cognitive complaints, and headache. None of the DMTs were predisposed to the development of residual symptoms after the initial infection. A total of 11.97% of patients had relapse three months prior or after SARS-CoV-2 infection. (4) Conclusion: Almost half of individuals with MS treated with different DMTs had residual symptoms after SARS-CoV-2 infection. None of the DMTs raised the probability of developing post-acute COVID symptoms.
format	article
author	Agata Czarnowska Katarzyna Kapica-Topczewska Olga Zajkowska Monika Adamczyk-Sowa Katarzyna Kubicka-Bączyk Natalia Niedziela Paweł Warmus Alicja Kalinowska-Łyszczarz Karolina Kania Agnieszka Słowik Marcin Wnuk Monika Marona Klaudia Nowak Halina Bartosik-Psujek Beata Lech Adam Perenc Małgorzata Popiel Marta Kucharska-Lipowska Monika Chorąży Joanna Tarasiuk Anna Mirończuk Jan Kochanowicz Anetta Lasek-Bal Przemysław Puz Katarzyna Maciejowska Sławomir Wawrzyniak Anna Niezgodzińska-Maciejek Anna Pokryszko-Dragan Ewa Gruszka Sławomir Budrewicz Marta Białek Jacek Zwiernik Anna Michałowska Krzysztof Nosek Beata Zwiernik Bożena Lewańczyk Waldemar Brola Alina Kułakowska
author_facet	Agata Czarnowska Katarzyna Kapica-Topczewska Olga Zajkowska Monika Adamczyk-Sowa Katarzyna Kubicka-Bączyk Natalia Niedziela Paweł Warmus Alicja Kalinowska-Łyszczarz Karolina Kania Agnieszka Słowik Marcin Wnuk Monika Marona Klaudia Nowak Halina Bartosik-Psujek Beata Lech Adam Perenc Małgorzata Popiel Marta Kucharska-Lipowska Monika Chorąży Joanna Tarasiuk Anna Mirończuk Jan Kochanowicz Anetta Lasek-Bal Przemysław Puz Katarzyna Maciejowska Sławomir Wawrzyniak Anna Niezgodzińska-Maciejek Anna Pokryszko-Dragan Ewa Gruszka Sławomir Budrewicz Marta Białek Jacek Zwiernik Anna Michałowska Krzysztof Nosek Beata Zwiernik Bożena Lewańczyk Waldemar Brola Alina Kułakowska
author_sort	Agata Czarnowska
title	Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland
title_short	Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland
title_full	Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland
title_fullStr	Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland
title_full_unstemmed	Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland
title_sort	symptoms after covid-19 infection in individuals with multiple sclerosis in poland
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/812471485cba43638a8b703fa750442d
work_keys_str_mv	AT agataczarnowska symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT katarzynakapicatopczewska symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT olgazajkowska symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT monikaadamczyksowa symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT katarzynakubickabaczyk symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT natalianiedziela symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT pawełwarmus symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT alicjakalinowskałyszczarz symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT karolinakania symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT agnieszkasłowik symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT marcinwnuk symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT monikamarona symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT klaudianowak symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT halinabartosikpsujek symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT beatalech symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT adamperenc symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT małgorzatapopiel symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT martakucharskalipowska symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT monikachorazy symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT joannatarasiuk symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT annamironczuk symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT jankochanowicz symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT anettalasekbal symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT przemysławpuz symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT katarzynamaciejowska symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT sławomirwawrzyniak symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT annaniezgodzinskamaciejek symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT annapokryszkodragan symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT ewagruszka symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT sławomirbudrewicz symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT martabiałek symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT jacekzwiernik symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT annamichałowska symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT krzysztofnosek symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT beatazwiernik symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT bozenalewanczyk symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT waldemarbrola symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland AT alinakułakowska symptomsaftercovid19infectioninindividualswithmultiplesclerosisinpoland
_version_	1718411754675896320

Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland

Ejemplares similares